Bicycle Therapeutics plc (NASDAQ:BCYC) COO Sells $64,504.02 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) COO Alistair Milnes sold 4,578 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $64,504.02. Following the completion of the sale, the chief operating officer now owns 100,724 shares of the company’s stock, valued at approximately $1,419,201.16. This represents a 4.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Bicycle Therapeutics Stock Performance

BCYC opened at $15.14 on Wednesday. The company has a market capitalization of $1.05 billion, a P/E ratio of -4.60 and a beta of 0.92. The company has a 50-day moving average of $19.09 and a 200-day moving average of $21.82. Bicycle Therapeutics plc has a 1-year low of $12.17 and a 1-year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. During the same period in the previous year, the company earned ($1.26) earnings per share. Bicycle Therapeutics’s quarterly revenue was down 50.0% on a year-over-year basis. As a group, sell-side analysts expect that Bicycle Therapeutics plc will post -3.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicycle Therapeutics

Large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in Bicycle Therapeutics by 105.1% during the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after purchasing an additional 1,038 shares during the last quarter. L & S Advisors Inc grew its position in shares of Bicycle Therapeutics by 2.4% during the 3rd quarter. L & S Advisors Inc now owns 59,735 shares of the company’s stock valued at $1,352,000 after buying an additional 1,400 shares during the last quarter. Assetmark Inc. bought a new stake in shares of Bicycle Therapeutics during the 3rd quarter valued at about $34,000. JPMorgan Chase & Co. raised its stake in Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after acquiring an additional 1,782 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Bicycle Therapeutics by 69.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after acquiring an additional 2,918 shares during the last quarter. 86.15% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. B. Riley dropped their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Needham & Company LLC restated a “buy” rating and issued a $38.00 target price on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. HC Wainwright dropped their price target on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating on the stock in a research note on Monday, December 16th. Finally, Stephens initiated coverage on shares of Bicycle Therapeutics in a research report on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $35.25.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.